← Back to Search

Anticoagulant

Dabigatran vs. Rivaroxaban for Atrial Fibrillation

N/A
Waitlist Available
Research Sponsored by Boehringer Ingelheim
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline (july 1, 2010) until end of the observation period (june 30, 2016), 6 years
Awards & highlights

Summary

The purpose of this study is to assess the safety and effectiveness of newly initiated dabigatran among patients diagnosed with non valvular atrial fibrillation (NVAF) in comparison to newly initiated rivaroxaban users and newly initiated apixaban users

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline (july 1, 2010) until end of the observation period (june 30, 2016), 6 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline (july 1, 2010) until end of the observation period (june 30, 2016), 6 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Overall Major Bleeding
Stroke Overall (Hemorrhagic, Ischemic, Uncertain)
Secondary outcome measures
All-cause Mortality
Hemorrhagic Stroke
Ischemic Stroke
+8 more

Trial Design

2Treatment groups
Experimental Treatment
Group I: Dabigatran vs. RivaroxabanExperimental Treatment1 Intervention
OAC treatment naïve NVAF patients with at least one prescription claim for dabigatran, rivaroxaban (new oral anticoagulant or NOAC).
Group II: Dabigatran vs. ApixabanExperimental Treatment1 Intervention
OAC treatment naïve NVAF patients with at least one prescription claim for dabigatran, or apixaban (new oral anticoagulant or NOAC).
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Rivaroxaban
FDA approved
Apixaban
FDA approved

Find a Location

Who is running the clinical trial?

Boehringer IngelheimLead Sponsor
2,534 Previous Clinical Trials
11,314,993 Total Patients Enrolled
70 Trials studying Atrial Fibrillation
1,228,708 Patients Enrolled for Atrial Fibrillation
Health ResearchTx, LLC (HRTX)UNKNOWN
inVentiv Health Clinical (iVH)UNKNOWN
~4908 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top